[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621435":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":34,"studyPopulation":22,"armGroups":35,"interventions":48,"overallOfficials":22,"centralContacts":57,"locations":66,"responsibleParty":81,"collaborators":83,"id":86,"slug":22,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":22,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":22,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":69,"whyStopped":22,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"iVeena Delivery Systems, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":22},[9,13,16,19],{"measure":10,"description":11,"timeFrame":12},"Visual acuity","Change from baseline in corrected distance visual acuity (CDVA) with Early Treatment Diabetic Retinopathy Study (ETDRS) in the study eye (SE) at all post-baseline visits. The change in ETDRS scores will be recorded as logMAR scores and letters missed on the eye chart. A logMAR of 0.0 corresponds to 20\u002F20 vision; higher values indicate greater myopia (near-sighted), and lower values indicate greater hyperopia (far-sighted) .","From enrollment to the end of treatment at 6 weeks",{"measure":14,"description":15,"timeFrame":12},"Change in eye assessments","Clinically significant Abnormalities in ocular assessments at any post-baseline visit",{"measure":17,"description":18,"timeFrame":12},"Punctal stenosis or Bloody discharge","Development of punctal stenosis or bloody discharge over the course of the study",{"measure":20,"description":21,"timeFrame":12},"Change in ocular assessments","Change from baseline in ocular symptoms assessment (discomfort, burning, irritation, photophobia, and redness) at all post-baseline visits.",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":29},"QUADRUPLE",[30,31,32,33],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Randomized, double-masked, controlled studies are the gold standard of clinical research. This is a randomized, vehicle-controlled, double-masked Phase 1 clinical study to assess the safety of IVMED-85 ophthalmic solution in healthy adult subjects. 36 subjects (ages 18-49) will be randomly and equally assigned to one of two treatment groups: vehicle ophthalmic solution or 0.20 mg\u002FmL IVMED-85 ophthalmic solution.\n\nAll subjects will dose twice daily (BID), morning and evening, in both eyes for 6 weeks. Subjects will attend 3 clinic visits (screening\u002Fbaseline, Day 21, and Day 42 at which safety will be assessed. If any treatment-related adverse events occur, additional visits to monitor for resolution and\u002For treatment, at the Investigator's discretion, with at least 1 such visit occurring months 3 after the last study visit.\n\nIn this study, the vehicle is the control treatment, chosen to help ensure that any effect observed in the IVMED-85 group is due to the active ingredient. IVMED-85 will be administered as an eye drop, a common route of administration.",[36,42],{"label":37,"type":38,"description":39,"interventionNames":40},"Vehicle ophthalmic solution","PLACEBO_COMPARATOR","Vehicle ophthalmic solution, administered twice a day",[41],"Drug: Vehicle Ophthalmic Solution",{"label":43,"type":44,"description":45,"interventionNames":46},"IVMED-85 ophthalmic solution","EXPERIMENTAL","IVMED-85 ophthalmic solution (0.20 mg\u002FmL)",[47],"Drug: IVMED-85 ophthalmic solution",[49,53],{"type":50,"name":43,"description":51,"armGroupLabels":52,"otherNames":22},"DRUG","IVMED-85 ophthalmic solution (0.20 mg\u002FmL), administer twice a day (morning and evening) in both eyes",[43],{"type":50,"name":54,"description":55,"armGroupLabels":56,"otherNames":22},"Vehicle Ophthalmic Solution","Vehicle ophthalmic solution, administer twice a day (morning and evening) in both eyes",[37],[58,63],{"name":59,"role":60,"phone":61,"phoneExt":22,"email":62},"David Evans, OD","CONTACT","901-761-4620","tneyedoc@mac.com",{"name":64,"role":60,"phone":61,"phoneExt":22,"email":65},"Ariel McNatt","Akalafat6060@gmail.com",[67],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":22},"Total Eye Care, P.A.","RECRUITING","Memphis","Tennessee","38119","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-90.04898,35.14953,{"lat":79,"lon":78},{"type":82,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[84],{"name":85,"class":6},"Lexitas Pharma Services, Inc.","100621435",false,"NCT07370584","A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults","A Randomized, Vehicle-Controlled, Double-Masked Study of the Safety of IVMED-85 Ophthalmic Solution in Healthy Adults","Inclusion Criteria:\n\n* Subjects who meet all the following inclusion criteria at Visit 1 will be eligible to enroll in the study. Ocular criteria apply to both eyes.\n\n  1. Age 18-49. -\n  2. Ability to voluntarily provide written informed consent. -\n  3. Being clinically healthy, as determined by the investigator. -\n  4. Willing and able to comply with clinic visits and study-related procedures. -\n  5. Willing and able to discontinue use of topical ocular medications, unless approved by investigator. Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of the study investigational product (IP). -\n  6. BCVA better than or equal to 0.2 logarithm of the minimum angle of resolution (logMAR) (20\u002F30 Snellen equivalent). -\n  7. Corneal thickness 450 to 670 μm. -\n  8. Intraocular pressure (IOP) ≤22 mmHg. -\n  9. Willingness to not wear mascara for 6 weeks of the study. -\n  10. Willingness to not swim in an indoor pool for 6 weeks of the study. -\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria at Visit 1 will not be eligible to enroll in the study. Ocular criteria apply to either eye.\n\n1. Participation in a clinical trial with the use of any investigational drug or treatment within 30 days prior to Visit 1 and duration of the study. -\n2. Known copper allergy, sensitivity, or processing disorder (e.g., Wilson's disease). -\n3. Presence of significant central corneal scarring or hydrops. -\n4. History or presence of punctal stenosis or bloody discharge. -\n5. History of or presence of nasolacrimal duct occlusion, nasolacrimal system trauma, nasolacrimal or eyelid cancer, ectropion or entropion, dacryocystitis, dacryoadenitis, chronic conjunctivitis, recurrent subconjunctival hemorrhage, trichiasis, distichiasis, or uncontrolled dry eye. -\n6. Previous cornea, glaucoma, eyelid, strabismus (exotropia or esotropia), or intraocular surgeries. -\n7. Current or previous ocular disorder, including but not limited to: strabismus (exotropia or esotropia), amblyopia, glaucoma, macular degeneration, cataract, retinal detachment or nystagmus, or abnormality of the central cornea, lens, iris, ciliary body, or central retina. -\n8. Presence of any medical condition predisposing the subject to craniofacial anomalies, degenerative myopia, or abnormal ocular refractive anatomy (e.g., osteogenesis imperfecta or Stickler, Down, Ehlers-Danlos, Donnai-Barrow, Treacher-Collins, or Apert\u002FCrouzon\u002F Pfeiffer syndrome). -\n9. Active or recent (within 2 weeks prior to screening) bacterial, viral, or allergic conjunctivitis. -\n10. Active allergies causing uncontrolled ocular and nasal symptoms. -\n11. Active sinusitis. -\n12. Current or previous hypothyroidism or hyperthyroidism. -\n13. Ongoing or recent (within 3 months prior to screening) chronic use of eyedrops containing preservatives such as benzalkonium chloride (BAK), Purite, or Polyquad. -\n14. History of uncontrolled gastroenteric reflux disease or deviated nasal septum. -\n15. If a female of childbearing potential (FOCBP):\n\n    1. Are pregnant or lactating.\n    2. Are unwilling to use an effective form of contraception (e.g., hormonal, oral, transdermal, implant, injection, or abstinence) for the duration of the study. -\n16. A male subject with a partner who is a FOCBP unwilling to use an effective form of contraceptives (e.g., barrier, hormonal, oral, transdermal, implant, injection, or abstinence) for either themselves or their partner, as appropriate, for the duration of the study. -",true,"ALL","18 Years","49 Years",{"count":97,"type":98},36,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group. The participants will receive eye drops twice daily for 6 weeks. Participants will not know which eyedrop they are taking.",[104],"Safety Study",[106,107,108],"eye drops","safety","myopia","2026-02-04",{"date":111,"type":112},"2026-02-05","ACTUAL",{"date":109,"type":112},{"date":115,"type":98},"2026-07",{"name":5,"class":6},1]